logo
NasdaqCM:CAPR logo

Capricor Therapeutics Community

NasdaqCM:CAPR Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 18 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

CAPR logo
Capricor Therapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts

FDA Priority Review And NS Pharma Partnership Will Empower Deramiocel

Key Takeaways FDA priority review of deramiocel and partnership with NS Pharma could drive significant revenue growth and market penetration. Expanded manufacturing capabilities and milestone payments enhance financial position, supporting demand and potential future growth.
View narrative
US$43.71
FV
85.5% undervalued intrinsic discount
103.05%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
7 days ago author updated this narrative